SeraCare Life Sciences Acquires KPL
The acquisition expands SeraCare's portfolio of products designed to help diagnostic researchers develop in vitro diagnostic assays.
SeraCare Life Sciences, which provides life science products for the diagnostic industry, acquired Kirkegaard and Perry Laboratories (KPL). KPL is a provider of antibodies and related reagents for the diagnostic and life sciences markets. With the acquisition, SeraCare has expanded its portfolio of products designed to help diagnostic researchers develop in vitro diagnostic assays through both off-the-shelf products and custom antibody design.
By acquiring KPL, SeraCare has built upon its position as a life science consumables provider for diagnostic research. KPL’s portfolio of products includes high quality immunochemicals for in vitro diagnostics, including primary and secondary antibodies as well as reagents and kits targeting ELISA, western blotting, immunohistology, protein labeling, nucleic acid labeling, sample preparation, protein purification, and recombinant protein detection and analysis. These products will assist SeraCare’s expansion from its core strength of providing biological products and control materials for infectious disease, women’s health, and genetic testing into oncology, autoimmune, allergy, and companion diagnostics.
Source: SeraCare
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
